<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="137761">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01765881</url>
  </required_header>
  <id_info>
    <org_study_id>1014301</org_study_id>
    <secondary_id>2011-000933-35</secondary_id>
    <nct_id>NCT01765881</nct_id>
  </id_info>
  <brief_title>Comparison Between 25 µg Vaginal Misoprostol Versus Slow Release Pessary PGE2: a French Multicentre Randomised Controlled Trial</brief_title>
  <acronym>CYTOPRO</acronym>
  <official_title>Comparison Between 25 µg Vaginal Misoprostol Versus Slow Release Pessary PGE2: Could we Used Low Dose Vaginal Misoprostol as a First Line Treatment for Induction of Labor ?</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Toulouse</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Toulouse</source>
  <oversight_info>
    <authority>France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      For about 10% of pregnancies, it is necessary to induce delivery for medical reasons.
      Prostaglandins alone can be used to perform cervical ripening in cases of  immature cervix.
      In France, dinoprostone is the own approved medication .  It is in the form of gel or
      sustained release device whose effectiveness and side effects are comparable. The vaginal
      misoprostol has no marketing authorization in France, but is sometimes used. Some data in
      the scientific literature have showed  that its use with low-dose (25 mcg) vaginally did not
      lead to more complications, was at least as effective and seems to be cost-effective
      compared with dinoprostone. Misoprostol with this dose and route of administration is now
      recommended by the American College of Obstetricians and Gynecologist (ACOG), Grade A (ACOG
      Practice Bulletin August 2009). This is not the case in France (French HAS  2008 Guidelines
      on induction of labor). According to HAS, the investigators still lack data on large samples
      to confirm the benefits of misoprostol 25 mcg vaginally, in terms of efficiency, rate of
      cesarean section, and lower cost compared to dinoprostone.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To show if the experimental treatment (25μg of intravaginal misoprostol) used for  induction
      of labor in singleton women ≥ 36 weeks gestation with an unfavorable cervix is not
      clinically and statistically inferior than the reference treatment , ie intravaginal
      dinoprostone sustained release (10mg), to compare the cost-effectiveness and to assess the
      differential tolerance of the two strategies.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2012</start_date>
  <completion_date type="Anticipated">September 2015</completion_date>
  <primary_completion_date type="Anticipated">September 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Cesarean rate for all indications</measure>
    <time_frame>24h</time_frame>
    <safety_issue>No</safety_issue>
    <description>Demonstrate that cesarian rate decreases with use of Misoprostol</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cost-effectiveness of two strategies (direct medical cost differential efficiency strategies measured by the Cesarean rate</measure>
    <time_frame>5 days</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <other_outcome>
    <measure>Tolerance of two strategies Misoprostol/ Dinoprostone</measure>
    <time_frame>5 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>Tolerance of two strategies:
Maternal hyperstimulation syndrome rate, rate of postpartum hemorrhage, maternal satisfaction.
neonatal rate of pH &lt;7.05 and  BD&gt; 12mmol / L,  rates Apgar score &lt;7 at 5 minutes, transfer rate in NICU</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">1200</enrollment>
  <condition>Benefits of Misoprostol 25 Mcg Vaginally,</condition>
  <condition>Efficiency</condition>
  <condition>Rate of Cesarean Section,</condition>
  <condition>Lower Cost Versus Dinoprostone</condition>
  <arm_group>
    <arm_group_label>Misoprostol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>one 25 micrograms capsule all 4 hours by intravaginal route</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dinoprostone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>one unique intravaginal sustained released of 10 milligrams</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Misoprostol</intervention_name>
    <description>administration of Misoprostol 25 micrograms capsule by intravaginal route all 4 hours</description>
    <arm_group_label>Misoprostol</arm_group_label>
    <other_name>CYTOTEC</other_name>
    <other_name>introduction of one  25 micrograms Misoprostol capsule by intravaginal route</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dinoprostone</intervention_name>
    <description>administration of one sustained released capsule of 10 milligrams by intravaginal route</description>
    <arm_group_label>Dinoprostone</arm_group_label>
    <other_name>PROPESS</other_name>
    <other_name>one intravaginal sustained released capsule of 10 milligrams</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  ≥ 18 years old

          -  singleton pregnancy

          -  Cephalic presentation

          -  Bishop ≤ 5

          -  ≤ 3 uterine contractions / 10 mn

          -  ≥ 36 weeks gestation

        Exclusion Criteria:

          -  uterine scar

          -  deceleration on CTG

          -  placenta praevia

          -  bleeding

          -  chorioamnionitis

          -  Fetal weight US ≥4500 g
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christophe Vayssière, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Toulouse</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Patrick Rozenberg, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>IH Poissy</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Romain Favre, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Strasbourg Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Christophe Vayssière, MD, PhD</last_name>
    <phone>05 67 77 13 79</phone>
    <phone_ext>0033</phone_ext>
    <email>vayssiere.c@chu-toulouse.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Mathieu Morin, Midwife</last_name>
    <email>morin.sf@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Vayssière Christophe</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christophe Vayssière, MD, PhD</last_name>
      <phone>05 67 77 13 79</phone>
      <phone_ext>0033</phone_ext>
      <email>vayssiere.c@chu-toulouse.fr</email>
    </contact>
    <contact_backup>
      <last_name>Mathieu Morin, Midwife</last_name>
      <phone>05 67 74 93 50</phone>
      <phone_ext>0033</phone_ext>
      <email>morin.sf@gmail.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>November 2013</verification_date>
  <lastchanged_date>November 8, 2013</lastchanged_date>
  <firstreceived_date>January 8, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Induction of labor</keyword>
  <keyword>cervical ripening</keyword>
  <keyword>misoprostol,</keyword>
  <keyword>prostaglandin</keyword>
  <keyword>cost-effectiveness</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Dinoprostone</mesh_term>
    <mesh_term>Misoprostol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
